A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study of PLB-002 (Anti-Claudin 6 ADC) in Adults With Advanced Solid Tumors
Latest Information Update: 06 Mar 2026
At a glance
- Drugs PLB 002 (Primary)
- Indications Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Testicular cancer
- Focus Adverse reactions
- Sponsors PrimeLink BioTherapeutics
Most Recent Events
- 03 Mar 2026 Status changed from not yet recruiting to recruiting.
- 01 Jan 2026 New trial record